Business Wire·Aug 17, 2026, 9:33 AM ET

People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides

REDEMPLO® (plozasiran) is listed in Germany's Lauer-Taxe® database for prescription, dispensing, & reimbursement following European Commission marketing authorization in June 2026.
The treatment is indicated as an adjunct to diet for adults with Familial Chylomicronaemia Syndrome (FCS) diagnosed via clinical symptoms or genetic testing.
REDEMPLO differs from other treatments by allowing administration based on clinical diagnosis without mandatory genetic confirmation.
The drug is administered as a subcutaneous injection once every three months.
European approval is based on the Phase 3 PALISADE study, which showed plozasiran significantly reduced median fasting triglyceride levels at the 25 mg dose compared to placebo (p <0.0001).
FCS is a rare metabolic disorder causing triglyceride levels typically exceeding 10 mmol/L, leading to high risks of acute pancreatitis & long-term complications.
Common adverse reactions observed in the study included hyperglycaemia (12.8%), headache (6.8%), nausea (4.7%), & injection site reaction (4.7%).
Arrowhead Pharmaceuticals announced Germany as the first EU focus for availability, with plans to expand to other European countries in the coming months.